Gland Pharma Ltd on Tuesday (August 5) reported a 49.9% spike in net profit at ₹215.4 crore for the first quarter of FY26, up from ₹143.7 crore in the year-ago quarter.
Revenue from operations increased 7.4% to ₹1,505.6 crore against ₹1,401.7 crore in Q1FY25.
At the operating level, EBITDA jumped 39% to ₹367.6 crore in the April-June quarter over ₹264.5 crore last year. The EBITDA expanded significantly to 24.4% versus 19% year-on-year.
R&D expenses & new drugs
The company reported total R&D expenses of ₹46 crore in Q1FY26, representing 4.4% of its revenue. During the quarter, the company launched 12 new molecules in regulated markets, including colistimethate, epinephrine, vancomycin (three new strengths), liraglutide, and acetaminophen bags.
Also Read: Gland Pharma shares gain up to 3% after USFDA closes inspection at Visakhapatnam unit
In terms of regulatory filings, one ANDA (abbreviated new drug application) was filed and nine were approved in Q1FY26, taking the cumulative total to 372 ANDA filings in the US, with 325 approved and 47 pending. The company continues to invest in its in-house complex pipeline, with six products already launched and three more in line for approval. Complex injectables are expected to remain a key focus for long-term growth, with more products being added to the pipeline.
Gland Pharma is also progressing on its co-development partnerships, with 15 products in development — seven under the 505(b)(2) pathway and eight as ANDAs. Commercialisation of these is expected to begin in FY28. Additionally, the company filed one ready-to-use (RTU) infusion bag product in the quarter, bringing the total number filed in the USA to 20, of which 14 have been approved. Ten more RTU products are under development, targeting a market size of approximately $767 million.
GLP-1 segment
In the GLP-1 segment, the company launched its first partnered product, liraglutide, in Q4FY25 and expanded its presence by launching it in the UK and Australia during Q1FY26. Gland Pharma is ramping up its GLP-1, pen, and cartridge manufacturing capacity from around 40 million to 140 million units. The company also received a GMP compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion, and inhalation.
Production facilities
Production at the Fontenay facility is progressing well, with improved order shipments following the commissioning of a new high-speed ampoule line. The site also received a GMP certificate from ANSM. The Hérouville facility is advancing steadily on tech transfer projects, and new tech-transfer products in vaccines and ophthalmic gel formats began commercial supply in Q1FY26, contributing to revenue growth.
Also Read: Gland Pharma shares have ‘value’, 23% upside potential despite poor execution, analyst says
A new pre-filled syringe line at Hérouville is on schedule to be operational in early 2026, which will significantly enhance capacity. The Braine-L’Alleud and Osny sites continue to perform well. Two new lyophilizers are being installed at the Braine-L’Alleud facility, with qualification expected to be completed by the end of 2025.
The results came after the close of the market hours. Shares of Gland Pharma Ltd ended at ₹1,964.45, down by ₹16.60 or 0.84%, on the BSE today (August 5).
